The global pharmaceutical space is growing fast. As per the F&S Report, it is growing at a rate of 6.4% each year and will reach USD 2,076 billion by 2029.
Anthem Biosciences has been part of this growing industry for years. The company works across the entire drug development process and supports both small and large pharmaceutical companies. With its strong foundation, Anthem is now planning to launch its IPO soon.
The Anthem Biosciences IPO lead manager is JM Financial Limited, Citigroup Global Markets India, and J.P. Morgan India and the registrar is KFin Technologies.
Check the Anthem Biosciences IPO DRHP and RHP for more details.
Note: The lock-in period for 50% of Smarten Power Systems’ stock concludes 30 days post-allocation, whereas the remaining portion is released from lock-in after 90 days.
Anthem Biosciences IPO is gaining attention for a reason. Here's everything about the company, like established year, headquarters, competitors and more.
If you are thinking of applying, make sure to check Anthem Biosciences IPO timeline and key financial details.
Here's a breakdown of the Anthem Biosciences IPO date.
Anthem Biosciences has a big fundraising goal. See how much capital they’re aiming to bring in through the IPO.
Since Anthem Biosciences is not raising any fresh money through this IPO and it’s just an offer-for-sale, the company won’t be receiving any funds from it. That’s why there’s no need to appoint a monitoring agency to track how the money is used.
Check the Anthem Biosciences IPO price before making your next move.
Bidding categories vary by investor type, here’s how the slots are divided.
You’ll need an active demat account to apply for the Anthem Biosciences IPO. Also, don't forget to check Anthem Biosciences IPO news.
Dive into the company’s financials to get a better idea of its strength and stability.
Know what are the risks and strengths of Anthem Biosciences.
Strengths
Works closely with small pharma and biotech companies
Strong team with experienced leaders and scientists
Offers full support across the drug development process
Trusted by repeat clients
Risks
Delays in regulatory approvals
Outdated or underperforming tech
Manufacturing not used fully
Cybersecurity and data safety issues
The Anthem Biosciences IPO GMP of ₹97 hints at a likely listing near ₹667. Don’t forget to go through the full IPO schedule and pricing details. Make sure you’ve reviewed all the IPO info before placing your bid.
Ready to invest? Place your IPO application for Anthem Biosciences shares today.
1. What is the price of Anthem IPO?
The Anthem Biosciences IPO price is between ₹540 to ₹570 per share, with each share having a face value of ₹2.
2. Who is the owner of Anthem Biosciences?
The founder and Managing Director of Anthem Biosciences is Ajay Bhardwaj.
3. What is the Anthem Biosciences IPO GMP?
The Anthem Biosciences IPO GMP is ₹97 and reports suggest strong investor interest. It shows how the stock may perform on the listing day.
4. What is the Anthem Biosciences IPO size?
The Anthem Biosciences IPO size is ₹3,395 crore, and it is completely an offer-for-sale (OFS). This means the company is not raising new money and will not get any funds from the IPO.
5. Do an investor need a demat account to apply for Anthem IPO?
Yes, you must have a demat account for the Anthem Biosciences IPO application. It is where your shares will be stored in electronic form.
